Irlanda - inglese - HPRA (Health Products Regulatory Authority)

glaxosmithkline (ireland) limited - amoxicillin sodium; clavulanic acid - powder for solution for injection/infusion - 500 mg/100 milligram(s) - combinations of penicillins, incl. beta-lactamase inhibitors; amoxicillin and enzyme inhibitor

Irlanda - inglese - HPRA (Health Products Regulatory Authority)

glaxosmithkline (ireland) limited - measles virus - schwarz strain live attenuated; mumps vaccine rit 4385 live attenuated; rubella virus (ra 27/3 strain) - powder and solvent for solution for injection in pre-filled syringe - 0 percent - measles vaccines; measles, combinations with mumps and rubella, live attenuated

Irlanda - inglese - HPRA (Health Products Regulatory Authority)

glaxosmithkline (ireland) limited - salmeterol xinafoate fluticasone propionate - powder for inhalation - 50/100mcg microgram

Irlanda - inglese - HPRA (Health Products Regulatory Authority)

glaxosmithkline (ireland) limited - salmeterol xinafoate fluticasone propionate - powder for inhalation - 50/250mcg microgram

Irlanda - inglese - HPRA (Health Products Regulatory Authority)

glaxosmithkline (ireland) limited - salmeterol xinafoate fluticasone propionate - powder for inhalation - 50/500mcg microgram

Unione Europea - inglese - EMA (European Medicines Agency)

smithkline beecham ltd - rosiglitazone, glimepiride - diabetes mellitus, type 2 - drugs used in diabetes - avaglim is indicated in the treatment of type 2 diabetes mellitus patients who are unable to achieve sufficient glycaemic control on optimal dosage of sulphonylurea monotherapy, and for whom metformin is inappropriate because of contraindication or intolerance.

Unione Europea - inglese - EMA (European Medicines Agency)

smithkline beecham plc - rosiglitazone - diabetes mellitus, type 2 - drugs used in diabetes - rosiglitazone is indicated in the treatment of type 2 diabetes mellitus:as monotherapy-in patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intoleranceas dual oral therapy in combination with-metformin, in patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin-a sulphonylurea, only in patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite monotherapy with a sulphonylureaas triple oral therapy in combination with-metformin and a sulphonylurea, in patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy (see section 4.4).

Regno Unito - inglese - MHRA (Medicines & Healthcare Products Regulatory Agency)

glaxosmithkline uk ltd - amoxicillin sodium; potassium clavulanate - powder for solution for injection - 500mg ; 100mg

Regno Unito - inglese - MHRA (Medicines & Healthcare Products Regulatory Agency)

glaxosmithkline uk ltd - amoxicillin sodium; potassium clavulanate - powder for solution for injection - 1000mg ; 200mg

Regno Unito - inglese - MHRA (Medicines & Healthcare Products Regulatory Agency)

haleon uk ltd - guaifenesin; phenylephrine hydrochloride; paracetamol - powder for oral solution - 200mg ; 12.2mg ; 1gram